Novo Nordisk Revenue 2006-2018 | NVO

Current and historical revenue for Novo Nordisk (NVO) from 2006 to 2018. The sum of all revenue fields included for a company's operating activities. The current revenue for Novo Nordisk as of March 31, 2018 is .
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.973B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $342.875B 16.39
Pfizer (PFE) United States $224.185B 13.80
Novartis AG (NVS) Switzerland $187.621B 16.09
Merck (MRK) United States $169.698B 15.17
AbbVie (ABBV) United States $149.801B 15.27
Sanofi (SNY) France $105.515B 13.36
GlaxoSmithKline (GSK) United Kingdom $101.582B 13.89
Eli Lilly (LLY) United States $97.721B 19.40
AstraZeneca (AZN) United Kingdom $94.553B 9.90
Bristol-Myers Squibb (BMY) United States $92.973B 18.29